{"id":20503,"date":"2015-07-23T18:26:01","date_gmt":"2015-07-23T16:26:01","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=20503"},"modified":"2015-07-23T18:31:03","modified_gmt":"2015-07-23T16:31:03","slug":"farmaceutica-sigma-tau-pharma-ceduta-a-baxalta-per-900-mln-di","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/farmaceutica-sigma-tau-pharma-ceduta-a-baxalta-per-900-mln-di\/","title":{"rendered":"Pharmaceuticals: Sigma Tau Pharma sold to Baxalta for 900 mln of $"},"content":{"rendered":"<p><a href=\"https:\/\/www.agi.it\/research-e-sviluppo\/notizie\/farmaceutica_sigma_tau_pharma_ceduta_a_baxalta_per_900_mln_dlr-201507231611-eco-rt10121\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\">TO<img decoding=\"async\" class=\"alignleft\" src=\"https:\/\/globalgenes.org\/wp-content\/uploads\/2013\/09\/Signma_Tau.png\" alt=\"\" \/>GI \u2013 Milan, 23 July<\/span><\/a>. \u2013 Sigma Tau Pharma was sold to Baxalta incorporated for 900 million dollars. The operation was completed today by Sigma Tau Finanziaria, a holding company in the pharmaceutical sector, which sold the subsidiary&#039;s 100% to Baxalta, the leading American group in the biopharmaceutical sector.<\/p>\n<p>The transaction has obtained clearance from the competent competition authorities, on the basis of the<a href=\"http:\/\/www.agi.it\/research-e-sviluppo\/notizie\/farmaceutica_sigma_tau_pharma_ceduta_a_baxter_per_900_mln_dollari-201505121803-eco-rt10233\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\">agreement signed last 12 <img loading=\"lazy\" decoding=\"async\" class=\"alignright\" src=\"http:\/\/www.sigma-tau.de\/assets\/Uploads\/Packshot_Oncaspar_D.jpg\" alt=\"\" width=\"203\" height=\"164\" \/>May<\/span><\/a>. Sigma Tau and Baxalta have also signed a production agreement according to which Sigma Tau will continue to produce the anticancer drug Oncaspar at the Indianapolis plant in the USA for 5 years. (AGI) .<\/p>\n<p>&nbsp;<\/p>","protected":false},"excerpt":{"rendered":"<p>AGI &#8211; Milano, 23 lug. &#8211; Sigma Tau Pharma e&#8217; stata ceduta a Baxalta incorporated per 900 milioni di dollari. L&#8217;operazione &#8211; si legge in una nota &#8211; e&#8217; stata perfezionata oggi da Sigma Tau finanziaria, societa&#8217; di partecipazioni nel settore farmaceutico, che ha venduto il 100% della controllata a Baxalta, gruppo americano leader nel &hellip;<\/p>","protected":false},"author":4,"featured_media":20507,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[53],"class_list":["post-20503","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-fusioniacquisizioni"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/20503","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=20503"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/20503\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/20507"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=20503"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=20503"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=20503"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}